Secondary Marketplace / Explore Private Companies / Obsidian Therapeutics IPO
Obsidian Therapeutics Obsidian Therapeutics IPO
$507.38MM
Series C Valuation, Apr 2024
Register for Details
For more details on financing and valuation for Obsidian Therapeutics, register or login.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in
Company Details
Obsidian Therapeutics is a clinical-stage biotechnology specializing in engineered cell and gene therapies with a mission to deliver transformative outcomes for patients with intractable diseases. The company utilizes drug-responsive domains for controlled protein function in therapeutics, aiming for targeted treatment solutions. Obsidian Therapeutics was founded by Michael Gilman, Steve Shamah, and Tariq Kassum in 2015 and is headquartered in Cambridge, MA.
Founded
2015
Forge Price 1
Price not yet available
Post-Money Valuation 3
$507.38MM
Total Funding
$325.04MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C

Learn More About Obsidian Therapeutics

To invest in Obsidian Therapeutics pre-IPO

Can you invest in Obsidian Therapeutics pre-IPO?

Obsidian Therapeutics is a privately held company and is not publicly traded, therefore investing in Obsidian Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Obsidian Therapeutics before it goes public?

You can seek to sell your shares in Obsidian Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Obsidian Therapeutics shares?

To determine the value of your Obsidian Therapeutics shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Obsidian Therapeutics shares. You can also learn more about how to sell your private shares before getting started.

Is Obsidian Therapeutics a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Obsidian Therapeutics potential IPO

Will Obsidian Therapeutics go IPO?

Obsidian Therapeutics has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2025.

What is Obsidian Therapeutics’ IPO price?

The Obsidian Therapeutics IPO price does not exist at this time, as Obsidian Therapeutics is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Obsidian Therapeutics register for Forge Markets, today.

When was Obsidian Therapeutics founded?

Obsidian Therapeutics was founded in 2015.

What is Obsidian Therapeutics funding to date?

Obsidian Therapeutics has raised $325.04MM to date.
Obsidian Therapeutics Major Investors
Gv
Amgen Ventures
Bristol Myers Squibb
Logos Capital
Atlas Venture
Surveyor Capital
Vertex Pharmaceuticals
Rtw Investments
Samsara Biocapital
Tcg Crossover Management
Takeda Ventures
Johnson & Johnson Innovation
Vertex Ventures Hc
Soleus Capital
Ra Capital Management
Wellington Management
Revelation Partners
Cowen Healthcare Investments
Deep Track Capital
Shangpharma Innovation
Paradigm BioCapital
T. Rowe Price Associates
Janus Henderson Investors
Blue Owl Capital
Pivotal Life Sciences
Foresite Capital
Novo Holdings
Alexandria Venture Investments
Woodline Partners
Samsara

Obsidian Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
04/03/2024 Series C $160.5MM $xx.xx $507.38MM Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Novo Holdings, Paradigm BioCapital, Ra Capital Management, Rtw Investments, Samsara, Surveyor Capital, Tcg Crossover Management, T. Rowe Price Associates, Wellington Management, Woodline Partners
Price per Share
$xx.xx
Shares Outstanding
84,567,145
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Novo Holdings, Paradigm BioCapital, Ra Capital Management, Rtw Investments, Samsara, Surveyor Capital, Tcg Crossover Management, T. Rowe Price Associates, Wellington Management, Woodline Partners
09/09/2021 Series B $115.04MM $xx.xx $278.56MM Amgen Ventures, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal Life Sciences, Ra Capital Management, Samsara, Soleus Capital, Surveyor Capital, Tcg Crossover Management, Vertex Pharmaceuticals, Vertex Ventures Hc
Price per Share
$xx.xx
Shares Outstanding
76,187,917
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal Life Sciences, Ra Capital Management, Samsara, Soleus Capital, Surveyor Capital, Tcg Crossover Management, Vertex Pharmaceuticals, Vertex Ventures Hc
12/06/2017 Series A-2 $12.03MM $xx.xx $116.85MM Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
Price per Share
$xx.xx
Shares Outstanding
12,025,212
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
12/06/2017 Series A-1 $30.2MM $xx.xx $116.85MM Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
Price per Share
$xx.xx
Shares Outstanding
26,747,257
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
12/06/2017 Series A-3 $7.27MM $xx.xx $116.85MM Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
Price per Share
$xx.xx
Shares Outstanding
4,948,612
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
Private Companies Exploring an IPO
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
CerebrasCerebras$40.08+9.9%$xx.xxSeries F-1$2.84B$xx.xx$85MM
CoreWeaveCoreWeave$1,149.84+18.78%$xx.xxSeries C$19B$xx.xx$1.15B
ChimeChime$24.86-0.04%$xx.xxSeries G$24.93B$xx.xx$1.1B
KlarnaKlarna$370.00-1.33%$xx.xxUnknown$6.7B$xx.xx--
TuroTuro$13.51-0.3%$xx.xxSeries E$1.24B$xx.xx$240.52MM
CircleCircle$24.71+2.49%$xx.xxSeries F$8.05B$xx.xx$401MM
NetskopeNetskope$11.07+2.98%$xx.xxSeries H$7.5B$xx.xx$300MM
Liquid DeathLiquid Death$9.47-0.11%$xx.xxSeries F-1$1.4B$xx.xx$67.61MM
CohesityCohesity$15.66-18.31%$xx.xxSeries H-1$4.69B$xx.xx$27.5MM
MNTNMNTN----$xx.xxSeries D$2.21B$xx.xx$119MM

Updated on: Jan 17, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.